Risk of esophageal cancer returning after immunotherapy and surgery
Part of Cancer, Digestive system clinical trials.
This study looks back at patients who received immunotherapy and chemotherapy before surgery for esophageal cancer, to see how often the cancer comes back after surgery. It may help doctors understand which patients benefit the most from this treatment approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and had surgery for esophageal cancer.
- Your cancer type is squamous cell carcinoma (a common type of esophageal cancer).
- You received a combination of immunotherapy (medicines that help your immune system fight cancer) and chemotherapy before your surgery.
- Your surgery was done with the goal of cure, and all visible cancer was removed completely.
- You had a special scan called a PET/CT after finishing the pre-surgery treatment and before the surgery.
- Your surgery took place between August 2020 and October 2025.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving radiation therapy based on how well the tumor responds to initial chemoimmunotherapy can improve outcomes for people with a certain type of esophageal cancer. The goal is to find a more personalized treatment approach that may be more effective and possibly reduce side effects.
This study tests whether giving additional immunotherapy after esophageal cancer surgery can help prevent the cancer from coming back. If you've already had chemotherapy and immunotherapy before surgery, this trial may offer a way to continue that benefit after your operation.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This study compares two standard approaches for treating esophageal cancer before surgery: chemotherapy combined with radiation versus chemotherapy combined with immunotherapy. The goal is to see which approach works better for shrinking tumors and improving outcomes in patients whose cancer is considered removable.
This trial tests if adding radiation before and after standard chemotherapy can help people whose esophageal cancer has come back after initial treatment. It aims to improve control of the cancer while keeping side effects manageable.
This trial looks at how well the tumor responded to chemotherapy or radiation before surgery, to see if that can help doctors decide next steps like additional treatment. It may help people with esophageal squamous cell cancer who had the tumor removed completely after initial therapy.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.